Novavax Inc said on Monday it has begun the Phase 1 clinical preliminary of a novel coronavirus antibody applicant and has selected the preliminary’s first members, with primer outcomes scheduled for July. The Maryland-based late-stage biotechnology organization in April said it distinguished the up-and-comer, NVX-CoV2373, with which it intended to utilize its Matrix-M adjuvant to…